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Introduction
HIV-1 resistance data to inform treatment sequencing are limited for children with virological failure on first- and second-line
antiretroviral therapy (ART) in Sub-Saharan Africa.
Methods
HIV-1-infected children aged 515 years were retrospectively identified from an ARTcohort in Cape Town, South Africa (2003 to
2010). First-line ART was either non-nucleoside reverse transcriptase inhibitor (NNRTI) or lopinavir/ritonavir-based (with the
exception of children B6 months old who received full-dose ritonavir as the sole protease inhibitor (PI) from 2004 to 2007).
Second-line ART was the alternative regimen.Treatment outcomes, including virological failure, loss to care, death or remaining
in care, were determined. Genotypic resistance testing was conducted on stored serum from children at first- or second-line
virological failure (two consecutive HIV-1 RNA levels  1000 copies/ml). International AIDS Society criteria defined resistance
mutations.
Results
Of 472 children starting first-line ART, 352 (75%) remained in care, 45 (9%) were lost and 4 (1%) died on first-line treatment.
Seventy-one (15%) had observed virological failure, and 37 of these children had specimens available for genotype testing. Eight
children (22%) had wild-type virus, seven (19%) had thymidine analog mutations (TAMs), 24 (65%) had NNRTI resistance and two
(5.4%) had multiple protease resistance (PR). Of the 78 children who received second-line ART, 54 (71%) remained in care, 6 (8%)
were lost and 1 (1%) died during second-line treatment. Fifteen (20%) had observed virological failure; 13 had samples available
for genotype. Three (23%) had wild-type virus, eight (62%) had TAMs, nine (69%) had NNRTI resistance, and five (38%) had
multiple PI resistance all of whom had received full-dose ritonavir.
Conclusion
Although virological failure was infrequent in children on first- and second-line ART, rates of observed resistance including
multiple PR resistance after failure were high. Reasons for high rates of resistance include use of full-dose ritonavir and continued
viremia.Wild-type virus was common, suggesting poor adherence or challenges in correct dosing. Genotype resistance testing in
children with virological failure may optimize selection of subsequent regimens and inform recommendations for sequencing of
existing ART.
Published 11 November 2012
Copyright: – 2012 Orrell C et al; licensee International AIDS Society.This is an open access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work
is properly cited.
Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection
Orrell C et al. Journal of the International AIDS Society 2012, 15(Suppl 4):18086
http://www.jiasociety.org/index.php/jias/article/view/18086 | http://dx.doi.org/10.7448/IAS.15.6.18086
1